Web-Based Treatments for Depression in HIV-Infected Individuals
Depression is a common comorbidity in people living with HIV, with lifetime prevalence estimates ranging from 22% to 61%.
HIV/AIDS ADVISOR
HIV/AIDS Advisor
-
-
HIV Seroconversion Despite PrEP Therapy
The study evaluated a cohort of 14 young black, men who have sex with men in Atlanta, Georgia, who had HIV seroconversion despite treatment with PrEP. -
The Effect of Chronic Pain on HIV Outcomes
Chronic pain is a frequent comorbidity in people living with HIV, with a 2014 systematic review finding a 54% point prevalence. -
Mental Health Problems in Adolescents With HIV: Overview & Expert Interview
Adolescents infected with HIV have a greater risk for psychiatric hospitalizations compared with those not infected with HIV. -
Dolutegravir Use During Pregnancy: What Are the Risks?
Early evidence of a heightened risk for birth defects with dolutegravir is concerning but remains to be fully established.
Early Prednisone Reduces TB-Related Immune Reconstitution Inflammatory Syndrome in PLWHIV
Prednisone during the first month of ART for those with HIV leads to a lower incidence of tuberculosis-related immune reconstitution inflammatory syndrome.
Combination of Lamivudine and Dolutegravir Effective in Treating HIV-1
Combination therapy of lamivudine plus dolutegravir has shown efficacy, safety, and tolerability in people with HIV-1 infection.
A New Pathway of HIV-2 Integrase Strand-Transfer Inhibitor Resistance
A new integrase inhibitors resistance pathway in HIV-2 infected patients has been identified rendering isolates that are highly resistant.
HPV Biomarkers Predict Risk for Anal Precancer in MSM and Who Have HIV
Among men who have HIV who also have sex with men, HPV-related biomarkers provide long-term risk stratification for anal precancers.
Journal Articles
Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
[published online June 15, 2018]. doi: 10.1016/S2352-3018(18)30091-2
[published online June 15, 2018]. doi: 10.1016/S2352-3018(18)30091-2
Fulcher JA, Hussain SK, Cook R, et al. Effects of substance use and sex practices on the intestinal microbiome During HIV-1 infection
[published online July 2, 2018]. J Infect Dis. doi: 10.1093/infdis/jiy349
[published online July 2, 2018]. J Infect Dis. doi: 10.1093/infdis/jiy349
Hoy JF, Richardson R, Ebeling PR, et al. Zoledronic acid is superior to tenofovir DF-switching for low bone mineral density in adults with HIV: a randomised trial
[published online June 20, 2018]. AIDS. doi: 10.1097/QAD.0000000000001911
[published online June 20, 2018]. AIDS. doi: 10.1097/QAD.0000000000001911
Jarvis JN, Leeme TB, Molefi M, et al. Short course high-dose liposomal amphotericin B for HIV-associated cryptococcal meningitis: a phase-II randomized controlled trial
[published online June 26, 2018]. Clin Infect Dis. doi: 10.1093/cid/ciy515
[published online June 26, 2018]. Clin Infect Dis. doi: 10.1093/cid/ciy515
Patient Education Materials
Want to read more?
Please login or register first to view this content.
Next post in HIV/AIDS Advisor
